NanoTemper launches Spectral Shift Technology

By The Science Advisory Board staff writers

March 28, 2022 -- NanoTemper Technologies has launched Spectral Shift technology within their Dianthus instrument, which the company said is built to handle the most challenging affinity-based screenings in drug discovery.

The development will aid in affinity-based screenings and drug discovery, which will alleviate challenges like targeting proteolysis-targeting chimeras, intrinsically disordered proteins, or fragment libraries, the company said.

NanoTemper's Dianthus instrument includes breakthrough Spectral Shift technology to handle the most challenging affinity-based screenings in drug discovery. Image courtesy of NanoTemper.

Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.